SpyGlass Pharma, Inc. Common Stock
NASDAQ:SGPBiotechnology
Healthcare
$29.68 +2.49%
+$0.45 today
- Market cap
- $993.14M
- Beta
- -0.34
- P/E (TTM)
- -14.1
- EPS (TTM)
- -$1.32
52W Low $17.06High $32.44
Volume 0.10M
Average 0.09M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$32.70M
FY 2025 · Annual
Investing Cash Flow
-$11.79M
FY 2025 · Annual
Financing Cash Flow
$124.58M
FY 2025 · Annual
Cash Flow Statement
USD
Metric | FY2025 Dec 2025 |
|---|---|
| Net Income | (39.87M) |
| Depreciation & Amortization | 612K |
| Deferred Income Tax | 0 |
| Stock-Based Compensation | 2.79M |
| Change in Working Capital | 2.45M |
| Accounts Receivables | (8K) |
| Inventory | 0 |
| Accounts Payables | 549K |
| Other Working Capital | 1.91M |
| Other Non-Cash Items | 1.32M |
| Operating Cash Flow | (32.7M) |
| Capital Expenditures | (789K) |
| Acquisitions (Net) | 0 |
| Purchases of Investments | (17M) |
| Sales of Investments | 6M |
| Other Investing Activities | 0 |
| Investing Cash Flow | (11.79M) |
| Debt Repayment | 0 |
| Common Stock Issued | 170K |
| Common Stock Repurchased | (1.45M) |
| Dividends Paid | 0 |
| Other Financing Activities | (1.47M) |
| Financing Cash Flow | 124.59M |
| Effect of Forex Changes | 0 |
| Net Change in Cash | 80.09M |
| Free Cash Flow | (33.49M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$39.9M
+ D&A$612.0K
+ Stock-Based Comp$2.8M
+ Deferred Tax$0
+ Working Capital$2.4M
+ Other Non-Cash$1.3M
= Operating Cash Flow-$32.7M
- Capex-$789.0K
= Free Cash Flow-$33.5M
Analysis
FY2025 free cash flow is -$33.5M. FCF conversion is 84.0% of net income. Operating cash flow was -$32.7M, with capex of -$789.0K. The largest bridge item is Stock-Based Comp at $2.8M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 12, 2026 | |
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 8-K | Current report | Oct 19, 2026 | |
| 8-K | Current report | Oct 1, 2026 | |
| 10-Q | Quarterly report | Aug 6, 2026 |
Does SGP generate free cash flow?
SpyGlass Pharma, Inc. Common Stock (SGP) generated -$33.49M of free cash flow in fiscal 2025.
How much operating cash flow does SGP produce?
Operating cash flow was -$32.70M, before capital expenditures of $789,000.00.
Continue the stock analysis
Jump to another research area for this company.